Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

HKG/3692 stock hub

HKG/3692 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HKG/3692is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

219.7B

Hong Kong Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

HKG/3692

In the news

Latest news · HKG/3692

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E31.9

P25 11.7P50 18.9P75 41.4

Trailing P/E35.1

P25 10.7P50 17.9P75 38.5

ROE17.3

P25 -14.7P50 2P75 9.4

ROIC117.6

P25 -10.4P50 1.9P75 10.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HKG/3692 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

236

Groups with data

Currency

CNY

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Cayman Islands
Country code	HK
Employees	9,347
Employees Change	358%
Employees Change Percent	3.98
Enterprise value	HKD 184.7B
Exchange	Hong Kong Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	KYG549581067
Last refreshed	2026-05-10
Market cap	HKD 219.7B
Price	HKD 36.24
Price currency	HKD
Rev Per Employee	1,789,202.2x
Sector	Healthcare
Sic	2834
Symbol	hkg/3692
Website	https://www.hspharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.81%
EV Earnings	29.88x
EV/EBIT	30.73x
EV/EBITDA	28.64x
EV/FCF	26.01x
EV/Sales	11.04x
FCF yield	3.23%
Forward P/E	31.92x
P/B ratio	5.58x
P/E ratio	35.06x
P/S ratio	13.14x
PE Ratio10 Y	31.87x
PE Ratio3 Y	30.69x
PE Ratio5 Y	27.03x
PEG ratio	4.79x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	35.94%
EBITDA Margin	38.37%
FCF margin	42.47%
Gross margin	89.89%
Gross Profit	HKD 15B
Gross Profit Growth	12.76%
Gross Profit Growth Q	29.25%
Gross Profit Growth3 Y	7.05%
Gross Profit Growth5 Y	9.82%
Net Income	HKD 6.2B
Net Income Growth	27.07%
Net Income Growth Q	47.03%
Net Income Growth Quarters	2%
Net Income Growth Years	3%
Net Income Growth3 Y	5.63%
Net Income Growth5 Y	16.63%
Pretax Margin	43.59%
Profit Margin	36.97%
Profit Per Employee	HKD 661,407
Profitable Years	10
ROA	9.44
Roa5y	7.07
ROCE	15.21
ROE	17.35
Roe5y	14.67
ROIC	117.6
Roic5y	60.21

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	54.02%
Cagr3y	37.98%
Cagr5y	2.95%
Div CAGR3	37.87%
EPS Growth	26.42
EPS Growth Q	45.76
EPS Growth Quarters	2
EPS Growth Years	3
EPS Growth3 Y	7.02
EPS Growth5 Y	16.39
FCF Growth	75.31%
FCF Growth Q	178.31%
FCF Growth3 Y	12.99%
FCF Growth5 Y	26.97%
OCF Growth	74.46%
OCF Growth Q	165.5%
OCF Growth10 Y	10.92%
OCF Growth3 Y	13.14%
OCF Growth5 Y	26.1%
Revenue Growth	22.57x
Revenue Growth Q	31.96x
Revenue Growth Quarters	6x
Revenue Growth Years	3x
Revenue Growth3 Y	7.5x
Revenue Growth5 Y	9.7x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	HKD 0.42
Assets	HKD 44.4B
Cash	HKD 35.1B
Current Assets	HKD 40.9B
Current Liabilities	HKD 5.1B
Debt	HKD 116.9M
Debt EBITDA	HKD 0.02
Debt Equity	HKD 0
Debt FCF	HKD 0.02
Equity	HKD 39.4B
Interest Coverage	1,708.2
Liabilities	HKD 5B
Long Term Assets	HKD 3.5B
Long Term Liabilities	HKD -13.4M
Net Cash	HKD 35B
Net Cash By Market Cap	HKD 15.94
Net Cash Growth	35.05%
Net Debt EBITDA	HKD -5.46
Net Debt Equity	HKD -0.89
Net Debt FCF	HKD -4.93
Tangible Book Value	HKD 39B
Tangible Book Value Per Share	HKD 6.43
WACC	7.27

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.09
Inventory Turnover	2.41
Net Working Capital	HKD -396.9M
Quick ratio	7.92
Working Capital	HKD 34.7B
Working Capital Turnover	HKD 0.6

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.52%
Dividend Growth	6.91%
Dividend Growth Years	2%
Dividend per share	HKD 0.43
Dividend Years	5
Dividend Yield	1.19%
Ex Div Date	2026-07-03
Last Dividend	HKD 0.23
Payout Ratio	36.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	53.97%
200-day SMA	37.08
3Y total return	162.75%
50-day SMA	35.64
50-day SMA vs 200-day SMA	50under200
5Y total return	15.64%
All Time High	46.7
All Time High Change	-22.4%
All Time High Date	2021-01-21
All Time Low	9.41
All Time Low Change	285.12%
All Time Low Date	2023-08-21
ATR	1.32
Beta	0.55
Beta1y	0.92
Beta2y	0.62
Ch YTD	0.44
High	37.68
High52	44.22
High52 Date	2026-01-15
High52ch	-18.05%
Low	36.06
Low52	21.4
Low52 Date	2025-05-12
Low52ch	69.35%
Ma50ch	1.69%
Price vs 200-day SMA	-2.27%
RSI	44.31
RSI Monthly	63.91
RSI Weekly	49.78
Sharpe ratio	1.21x
Sortino ratio	1.89
Total Return	0.67%
Tr YTD	0.44
Tr1m	-7.93%
Tr1w	-3.05%
Tr3m	-0.66%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	HKD 6B
Operating Income Growth	21.14
Operating Income Growth Q	72.2
Operating Income Growth3 Y	8.39
Operating Income Growth5 Y	17.49
Operating margin	35.94

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,239,064,072%
Net Borrowing	-25,770,829.5
Shares Insiders	15.24%
Shares Institutions	8.91%
Shares Out	6,062,955,423
Shares Qo Q	0.82%
Shares Yo Y	0.52%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	HKD 6.9B
Average Volume	8,218,265.65x
Bv Per Share	6.5
CAPEX	HKD -396.6M
Ch1m	-7.93
Ch1w	-3.05
Ch1y	52.27
Ch3m	-0.66
Ch3y	152.4
Ch5y	9.65
Ch6m	-1.58
Change	-3.82%
Change From Open	-3.82
Close	37.68
Days Gap	0
Depreciation Amortization	419,581,210.3
Dollar Volume	289,971,859.4
Earnings Date	2026-05-18
EBIT	HKD 6B
EBITDA	HKD 6.4B
EPS	HKD 1.03
F Score	5
FCF	HKD 7.1B
FCF EV Yield	3.84x
FCF Per Share	HKD 1.17
Financing CF	1,729,440,663
Fiscal Year End	December
Founded	1,995
Graham Number	12.20314
Graham Upside	-66.33
Income Tax	HKD 1.1B
Investing CF	-7,961,676,590
Is Primary Listing	1
Last Earnings Date	2026-03-29
Last Report Date	2025-12-31
Lynch Fair Value	HKD 16.95
Lynch Upside	-53.22
Ma150	37.39
Ma150ch	-3.07%
Ma20	38.34
Ma20ch	-5.48%
Net CF	1,208,754,522
Next Earnings Date	2026-05-18
Open	37.68
P FCF Ratio	30.94
P OCF Ratio	29.3
Payment Date	2025-10-30
Position In Range	11.11
Ppne	3,661,215,078.1
Price Date	2026-05-08
Price EBITDA	HKD 34.25
Ptbv Ratio	5.64
Relative Volume	0.96x
Revenue	16,723,672,957x
SBC By Revenue	0.95x
Share Based Comp	159,430,099
Tax By Revenue	6.62x
Tax Rate	15.19%
Tr6m	-1.58%
Volume	8,001,431
Z Score	23.84

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

HKG/3692 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.2%

$0.43 annual per share

Payout ratio

+36.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

2 consecutive years of growth

Total shareholder yield

+0.7%

Next ex-dividend date: 2026-07-03

Performance

HKG/3692 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HKG/3692?

Insider, institutional, and short-interest positioning.

Institutional ownership

+8.9%

Share of float held by funds and institutions

Insider ownership

+15.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.5%

Negative means the company is buying back shares.

Technical

HKG/3692 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.3

Neutral momentum band

Price vs 200-day MA

-2.3%

50/200-day relationship not available

Beta (5Y)

0.55

Less volatile than the market

Sharpe ratio

1.21

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HKG/3692

Hub-level FAQ points readers to the deeper analysis pages.

What is the current hkg/3692 stock rating?

hkg/3692 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full hkg/3692 analysis?

The full report lives at /stocks/hkg/3692/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for hkg/3692?

The latest report frames hkg/3692 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the hkg/3692 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.